Introduction
============

The incidence and mortality of lung cancer are higher.[@b1-ott-11-4781] Lung cancer patients are always diagnosed at an advanced stage.[@b2-ott-11-4781] Chemotherapy and targeted therapy are the standard treatments for advanced non-small-cell lung cancer (NSCLC). But not all patients can get benefit from these therapies.[@b3-ott-11-4781]--[@b5-ott-11-4781] Therefore, it is very necessary to search a new treatment for NSCLC patients.

Immunotherapy has a good result in lung cancer patients. Many clinical trials, such as Checkmate-017, Checkmate-057, Keynote-010, Keynote-024, and OAK, showed that anti-programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) monoclonal antibodies could improve the objective response rate (ORR) and prolong the overall survival (OS) in NSCLC patients. The anti-PD-1/PD-L1 monoclonal antibodies have been approved for the standard NSCLC treatment by the US Food and Drug Administration.[@b6-ott-11-4781]--[@b10-ott-11-4781]

Similar to the targeted therapy, not all lung cancer patients can benefit from anti-PD-1/PD-L1 monoclonal antibodies. Only \~20% of NSCLC patients can get benefit from the PD-1/PD-L1 inhibitors,[@b7-ott-11-4781],[@b8-ott-11-4781],[@b10-ott-11-4781] and resistance is an inevitable problem.[@b11-ott-11-4781] One study reported that when the patients faced the resistance of PD-1/PD-L1 inhibitor, T-cell immunoglobulin and mucin-domain containing-3 expression was significantly increased, which suggested that the resistance of PD-1 inhibitor might be related to other immunological checkpoints compensatory high expression.[@b12-ott-11-4781]

Lymphocyte-activation gene-3 (LAG-3; CD 223) is another important immune checkpoint in lung cancer,[@b13-ott-11-4781] which can bind a non-holomorphic region of major histocompatibility complex class II (MHC class II) with greater affinity than CD 4.[@b14-ott-11-4781],[@b15-ott-11-4781] LAG-3 can inhibit the cancer immune response and play a complicated role in the immune system. Soluble LAG-3 (sLAG-3) can induce dendritic cells to mature and attack tumor cells.[@b16-ott-11-4781] In our previous study, we reported that the LAG-3 expression was correlated with PD-1/PD-L1 expression in NSCLC patients and was related to poor prognosis. In this study, we detected the serum sLAG-3 level in NSCLC patients.

Methods
=======

Patients
--------

From January 2016 to June 2017, 247 hospitalized patients were continuously enrolled in this study from Shanghai Pulmonary Hospital. Most of the serum samples were collected within 2 days prior to test. Samples were stored at −80°C without repeated freeze and thaw. The feature of samples was blinded to the test before and after detecting sLAG-3. Blood samples were obtained before diagnosis and receiving any anticancer treatment. All participates signed the informed consent form. Pulmonary benign and NSCLC patients were diagnosed by histology. Lung cancer stages were categorized by seventh edition of International Association for the Study of Lung Cancer (IASLC) TNM staging system. The protocol was approved by the Shanghai Pulmonary Hospital, Tongji University.

ELISA for sLAG-3
----------------

sLAG-3 was detected by enzyme-linked immunosorbent assay (ELISA) kit (Uscn, Wuhan, China). Every sample was repeated three times.

Statistical analysis
--------------------

We performed statistical analysis by SPSS 17.0. Chi-square tests were used to analyze the clinical data between benign diseases and NSCLC. The measurement material used the rank sum test. All statistics were two-sided, and statistical significance was defined as *p*\<0.05.

Results
=======

Patient characteristics
-----------------------

Two-hundred forty-seven hospitalized patients were continuously enrolled in this study from Shanghai Pulmonary Hospital. Of them, 71 had benign diseases and 176 were NSCLC patients. [Table 1](#t1-ott-11-4781){ref-type="table"} shows the clinical data of all cases included in this study. In benign pulmonary diseases group, 53 (74.6%) were males and 18 (25.4%) were females. Eight (11.3%) patients were \>70 years old. Thirty-nine (55.9%) patients had a smoking history. In the NSCLC group, there were 41 (23.3%) females. Nineteen (10.8%) were \>70 years old. Ninety-nine (56.3%) patients had a smoking history.

sLAG-3 in different patients
----------------------------

We did a subanalysis in patients with benign pulmonary diseases; the sLAG-3 levels were non-significant between sex, age, and smoking status. In NSCLC patients, the sLAG-3 levels were non-significant between sex, age, smoking status, and pathology. The sLAG-3 levels were significantly higher in stage I--II NSCLC than in stage III--IV (*p*\<0.001; [Table 2](#t2-ott-11-4781){ref-type="table"}).

Discussion
==========

To our knowledge, this is the first study to analyze serum sLAG-3 in NSCLC patients. In our previous study, we detected LAG-3 expression in NSCLC by immunohistochemistry. We reported that LAG-3 expression was correlated with PD-1/PD-L1 expression and was related to poor prognosis in NSCLC patients.[@b17-ott-11-4781] In this study, we found that the serum sLAG-3 levels were significantly higher in early-stage NSCLC.

Immunotherapy has been widely recognized in the treatment of lung cancer. Anti-PD-1/PD-L1 monoclonal antibodies have been widely used in NSCLC.[@b6-ott-11-4781]--[@b10-ott-11-4781] Although anti-PD-1/PD-L1 monoclonal antibodies have a good result in NSCLC patients, not all patients can get benefits from them. Some biomarkers can partly predict the efficacy of anti PD-1/PD-L1 monoclonal antibodies, such as PD-1, PD-L1 expression, and tumor mutation burden.[@b6-ott-11-4781]--[@b10-ott-11-4781] Whether other molecular markers can predict the results of PD-1/PD-L1 inhibitor needs to be explored. LAG-3 is another important immune checkpoint.[@b13-ott-11-4781],[@b17-ott-11-4781] LAG-3 can inhibit cancer immunity by negatively regulating T cell proliferation, activation, and homeostasis in cancer patients. In gastric cancer, LAG-3 and PD-1 expression on T cells impaired the postsurgery cell-mediated immunity.[@b18-ott-11-4781] LAG-3 was highly expressed in hepatocellular carcinoma.[@b19-ott-11-4781] Our group reported that LAG-3 was correlated with PD-1/PD-L1 expression, and higher expression of LAG-3 predicted poor prognosis in NSCLC.[@b17-ott-11-4781] sLAG-3 plays different functions from LAG-3. sLAG-3 can induce dendritic cells attacking cancer cells.[@b20-ott-11-4781],[@b21-ott-11-4781] sLAG-3 can be detected in patient serum by ELISA.[@b22-ott-11-4781] In this study, we found that sLAG-3 in NSCLC serum was correlated with the stages of NSCLC. The advanced lung cancer patients had the lower sLAG-3 expression. This might be related to the advanced disease patients having poor cancer immune response. Thus, increasing sLAG-3 level in advanced lung cancer might be a promising treatment in NSCLC patients.

There are some limitations in this study. First, we lacked the data of ORR and OS. Second, tumor tissue LAG-3, PD-1, and PD-L1 expressions should be analyzed in these patients. Furthermore, we will prospectively compare serum sLAG-3 level with tumor LAG-3, PD-1, and PD-L1 expressions and analyze the correlation of sLAG-3 with survival data in a large-scale study.

Conclusion
==========

We detected sLAG-3 in NSCLC patients' serum and found that sLAG-3 was significantly lowly expressed in advanced-stage NSCLC. LAG-3 is an important immune checkpoint and may have synergistic function with PD-1/PD-L1. sLAG-3 can improve the immune response of cancer. Whether sLAG-3 could become a new treatment and serve as a liquid biopsy biomarker for lung cancer immunotherapy need to be further explored.
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###### 

Clinical data of all cases

  Characteristic       Benign pulmonary diseases   NSCLC        *p*-value
  -------------------- --------------------------- ------------ -----------
  Sex, n (%)                                                    
   Female              18 (25.4)                   41 (23.3)    0.743
   Male                53 (74.6)                   135 (76.7)   
  Age (years), n (%)                                            
   ≤70                 63 (88.7)                   157 (89.2)   1.000
   \>70                8 (11.3)                    19 (10.8)    
  Smoker, n (%)                                                 
   Smoker              39 (55.9)                   99 (56.3)    0.888
   Non-smoker          32 (45.1)                   77 (43.8)    
  Stage, n (%)                                                  
   I--II               --                          103 (58.5)   
   III--IV             --                          73 (41.5)    

**Abbreviation:** NSCLC, non-small-cell lung cancer.

###### 

sLAG-3 in different groups

                            Benign pulmonary diseases   *p*-value   NSCLC    *p*-value   Total    *p*-value
  ------------------------- --------------------------- ----------- -------- ----------- -------- -----------
  Sex, mean rank                                                                                  
   Female                   37.67                       0.692       94.44    0.394       131.49   0.356
   Male                     35.43                                   86.70                121.65   
  Age (years), mean rank                                                                          
   ≤70                      35.94                       0.942       88.63    0.924       124.10   0.948
   \>70                     36.50                                   87.45                123.15   
  Smoker, mean rank                                                                               
   Smoker                   34.11                       0.484       87.25    0.774       120.33   0.473
   Non-smoker               37.55                                   89.47                126.90   
  Stage, mean rank                                                                                
   I--II                    --                          --          111.77   \<0.001     --       --
   III--IV                  --                                      55.66                --       
  Pathology, mean rank                                                                            
   Benign diseases          --                          --          --       --          132.02   0.262
   NSCLC                    --                                      --                   120.76   
  Subpathology, mean rank                                                                         
   Adenocarcinoma           --                          --          94.79    0.158       --       --
   Non-adenocarcinoma       --                                      83.83                --       

**Abbreviations:** NSCLC, non-small-cell lung cancer; sLAG-3, soluble LAG-3.
